imvt-1402
mAbexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
8
Phase 3
1
Phase 4
0
Earliest trial started Dec 31, 2024 (NCT06727604)
Timeline
Indications
Mechanism of action
- IgG receptor FcRn large subunit p51INHIBITOR
FCGRT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07286006 | Phase 2 | Feb 28, 2026 | Immunovant Sciences GmbH |
| NCT06979531 | Phase 2 | Jun 30, 2025 | Immunovant Sciences GmbH |
| NCT07018323 | Phase 2 | Jun 19, 2025 | Immunovant Sciences GmbH |
| NCT07039916 | Phase 3 | May 27, 2025 | Immunovant Sciences GmbH |
| NCT07032662 | Phase 2 | Mar 18, 2025 | Immunovant Sciences GmbH |
| NCT06980805 | Phase 2 | Feb 19, 2025 | Immunovant Sciences GmbH |
| NCT06754462 | Phase 2 | Jan 10, 2025 | Immunovant Sciences GmbH |
| NCT06727604 | Phase 2 | Dec 31, 2024 | Immunovant Sciences GmbH |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunovant Sciences GmbH | For profit | 8 | 8 | 2 | 2024 |
1 organizations
Page 1 / 1